Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110864 · ClinicalTrials.gov registry record · Phase 2
Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Wellstat Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00110864 is a Phase 2 study that has completed, run by Wellstat Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT00110864, a Phase 2 study, has completed, sponsored by Wellstat Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.
Interventions
- DRUG Insulin
- DRUG PN2034
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110864
The ClinicalTrials.gov registry entry for NCT00110864 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wellstat Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin is the first listed.
NCT00110864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110864 about?
NCT00110864 is a clinical study titled "Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes". This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.
What is the current status of trial NCT00110864?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2005-05. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00110864?
The interventions under investigation include: Insulin (DRUG), PN2034 (DRUG).
Who is sponsoring clinical trial NCT00110864?
This trial is sponsored by Wellstat Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.